Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.52 CAD | -7.14% | -14.75% | +76.27% |
25/04 | NurExone Biologic Announces OTCQB Listing And DTC Eligibility | MT |
02/04 | NurExone Biologic Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 25.01M 34.21M 2.09B |
---|---|---|---|---|---|
Net income 2024 * | -4M -5.47M -334M | Net income 2025 * | -4M -5.47M -334M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-4.22
x | P/E ratio 2025 * |
-4.22
x | Employees | 12 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.95% |
1 day | -7.14% | ||
1 week | -14.75% | ||
Current month | -10.34% | ||
1 month | -20.00% | ||
3 months | +8.33% | ||
6 months | +89.09% | ||
Current year | +76.27% |
Managers | Title | Age | Since |
---|---|---|---|
Lior Shaltiel
CEO | Chief Executive Officer | - | 01/21/01 |
Eran Ovadya
DFI | Director of Finance/CFO | - | 15/22/15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jay Richardson
BRD | Director/Board Member | 78 | 03/22/03 |
Gadi Riesenfeld
BRD | Director/Board Member | 79 | 06/23/06 |
Yoram Drucker
CHM | Chairman | 59 | 01/20/01 |
Date | Price | Change | Volume |
---|---|---|---|
13/24/13 | 0.52 | -7.14% | 23,000 |
10/24/10 | 0.56 | -1.75% | 33,500 |
09/24/09 | 0.57 | -3.39% | 22,465 |
08/24/08 | 0.59 | +1.72% | 14,050 |
07/24/07 | 0.58 | -4.92% | 37,000 |
Delayed Quote Toronto S.E., May 14, 2024 at 12:05 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+76.27% | 25.01M | |
+26.37% | 48.16B | |
-1.01% | 41.73B | |
+46.00% | 41.03B | |
-5.31% | 28.77B | |
+9.34% | 25.59B | |
-21.69% | 18.96B | |
+6.23% | 12.92B | |
+26.99% | 12.03B | |
-3.38% | 11.77B |
- Stock Market
- Equities
- NRX Stock